This segment focuses on the research, development, and commercialization of innovative therapeutics for various cancers, including hematological malignancies and solid tumors. CASI Pharmaceuticals is actively involved in clinical trials for products like CNCT19 (CD19 CAR-T) for B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL), and BI-1206, which is in Phase I/II trials in combination with anti-PD1 therapy Keytruda for solid tumors and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL. The company also has CB-5339 in Phase I clinical trials for acute myeloid leukemia, myelodysplastic syndrome, and solid tumors and lymphomas. The segment leverages advanced technologies such as CAR-T cell therapy and small molecule inhibitors to address unmet medical needs in oncology. The patient impact is significant, aiming to improve survival rates and quality of life for cancer patients. Market positioning is enhanced through strategic partnerships and collaborations, such as with Juventas Cell Therapy Ltd. Future opportunities include expanding the product pipeline and geographic reach, particularly in China. Regulatory and clinical aspects are crucial, with a focus on obtaining FDA and other regulatory approvals. This segment is a core driver of CASI's growth strategy.

This segment concentrates on developing and commercializing therapies for hematological disorders, including multiple myeloma and other blood-related cancers. CASI offers EVOMELA, an intravenous formulation of melphalan for conditioning treatment prior to stem cell transplantation and as a palliative treatment for multiple myeloma. The company also has CID-103 for multiple myeloma. The segment utilizes advanced pharmaceutical formulations and drug delivery technologies to improve treatment efficacy and patient outcomes. The patient impact is focused on providing effective treatments for life-threatening blood cancers and improving patient survival and quality of life. Market positioning is strengthened through strategic partnerships and distribution agreements. Future opportunities include expanding the product portfolio and exploring new therapeutic approaches. Regulatory and clinical aspects are critical, with a focus on obtaining regulatory approvals and conducting clinical trials to demonstrate safety and efficacy. This segment is a key component of CASI's commitment to addressing unmet medical needs in hematology.